![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
C Schmauss and TL Yaksh
The intrathecal administration of mu (morphine) and delta (D-Ala2-D- Leu5-enkephalin) but not kappa agonists (ethylketocyclazocine, bremazocine and U50488H) or partial agonists (nalbuphine and buprenorphine) produced a dose-dependent inhibition of all cutaneous thermal (hot plate and tail-flick) responses in the rat. In contrast, on visceral chemical tests (writhing), mu and kappa agonists but not delta agonists exerted a powerful suppression of the response. Whereas the ED50 of morphine on the cutaneous thermal tests did not differ from that observed on the visceral chemical test, agents with significant mu and delta activity (metkephamid and beta-endorphin) showed a prominent reduction in activity on the writhing as compared with the hot plate and tail-flick. Systemic naloxone resulted in a dose-dependent antagonism of the effect of all intrathecal agents. Estimation of the pA2 of mu agents indicated no difference on the hot plate/tail-flick and writhing (pA2 approximately 7). Kappa ligands were selectively resistant to antagonism with naloxone pA2 values for those agonists ranging from 5.9 to 6.6. These observations suggest that there are three discriminable populations of receptors in the spinal cord whose activation results in a selective modulation of the response of the animal to noxious stimuli. In addition, the selective effects of the delta agonists on cutaneous thermal and kappa agonists on visceral chemical suggest a differential coding of spinal afferents through which these stimuli are transmitted.
This article has been cited by other articles:
|
|
 |
|
  I. Kondo, J. C. G. Marvizon, B. Song, F. Salgado, S. Codeluppi, X.-Y. Hua, and T. L. Yaksh Inhibition by Spinal {micro}- and {delta}-Opioid Agonists of Afferent-Evoked Substance P Release J. Neurosci., April 6, 2005; 25(14): 3651 - 3660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Tejwani and A. K. Rattan The Role of Spinal Opioid Receptors in Antinociceptive Effects Produced by Intrathecal Administration of Hydromorphone and Buprenorphine in the Rat Anesth. Analg., June 1, 2002; 94(6): 1542 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yaksh and D. J. Birnbach Intrathecal Nalbuphine After Cesarean Delivery: Are We Ready? Anesth. Analg., September 1, 2000; 91(3): 505 - 508. [Full Text] [PDF]
|
|
|
|
|
|
X. Culebras, G. Gaggero, J. Zatloukal, C. Kern, and R.-A. Marti Advantages of Intrathecal Nalbuphine, Compared with Intrathecal Morphine, After Cesarean Delivery: An Evaluation of Postoperative Analgesia and Adverse Effects Anesth. Analg., September 1, 2000; 91(3): 601 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Bartok and R. M. Craft Sex Differences in Opioid Antinociception J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 769 - 778. [Abstract] [Full Text]
|
|
|
|
|
|
J. Ho, A. J. Mannes, R. Dubner, and R. M. Caudle Putative kappa-2 Opioid Agonists Are Antihyperalgesic in a Rat Model of Inflammation J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 136 - 141. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
